10% OFF Crypto | 3rd Party Tested | FREE Worldwide Shipping $400+ ($750+ for USA)
Menu
Cart
ara-290 lyophilized peptide vial
edge peptides ara-290 16 mg janoshik test
ara-290 peptide vials container edge peptides

ARA-290 16mg – 10 Vial Box (160mg Total)

$330.0

Cost per vial $: 33

Buy phosphate-buffered ARA-290 16 mg (one 10-vial box). All orders are shipped wholesale in unbranded packaging. Worldwide 7 – 14 day shipping to the USA, UK, AUS & NZ.

Bulk discounts
Quantity Bulk Discount Price
210%$297.0
3-515%$280.5
6-1020%$264.0
SKU: ARA Category:

Description

ARA-290 is a synthetic peptide derived from erythropoietin (EPO) that has been studied for its tissue-protective properties. Research suggests it may help reduce inflammation and support nerve repair, helping address conditions involving nerve damage and inflammatory responses.

Minimum order quantity: one box (10 vials x 16 mg). 

Note: Our ARA-290 is buffered with phosphate so that it can be reconstituted with regular bacteriostatic water.

Note #2: Product images show branded labels for illustration purposes only. All peptides are shipped in wholesale, unbranded packaging. You can see an actual example photo of the peptide vials and container above.

Additional information

Purity

≥99.0%
Molar Mass

1257.3 g/mol
Molecular Formula

C₅₁H₈₄N₁₆O₂₁
Sequence

Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
Cost per vial $

33
  1. van Velzen, Monique, et al. "ARA 290 for treatment of small fiber neuropathy in sarcoidosis." Expert opinion on investigational drugs 23.4 (2014): 541-550.
  2. Dahan, Albert, et al. "ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density." Molecular medicine 19 (2013): 334-345.
  3. Swartjes, Maarten, et al. "ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response." Molecular pain 10 (2014): 1744-8069.
  4. Brines, Michael, et al. "ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes." Molecular medicine 20 (2014): 658-666.
  5. Heij, Lara, et al. "Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study." Molecular medicine 18 (2012): 1430-1436.

ARA-290 CoA (2024)

ARA-290 Janoshik Test (July 2025)

Related products